MarketCap
Facebook
X
Telegram
Deciphera Pharmaceuticals Balance Sheet 2023-2011 | DCPH
Brief overview of Deciphera Pharmaceuticals's balance sheet structure
Balance sheet changes are traced across five available annual reports between 2019 and 2023.
Assets finished at $473.6 million versus $622.4 million initially, losing -23.9%. The balance sheet contracted.
Liability growth of +61.5% exceeded asset growth of -23.9%, increasing reliance on outside funding.
Equity funds 74.1% of assets versus 87.8% initially. This creates a conservative balance sheet structure.
The period ended with net cash: net debt stood at -$57.6 million. This supports financial flexibility.
The cash reserve occupies 17.6% of the balance sheet, previously 19.3%. It is one marker of short-term resilience.
The balance sheet carries negative retained earnings of -$1.4 billion. The figure may result from accumulated losses or an active capital return policy.
Overall picture
Deciphera Pharmaceuticals's financial structure is not clear-cut. Asset scale alone does not resolve questions about how those assets are funded.
Annual Balance Sheet Deciphera Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-57.6 M | -35.6 M | -56.2 M | -105 M | -103 M | -282 M | -195 M | -56 M | -24.1 M | - | - | - | - |
Long Term Debt |
22.4 M | 25.9 M | 28 M | 28.8 M | 15.9 M | 11.3 M | 1.29 M | 1.48 M | 1.68 M | - | - | - | - |
Long Term Debt Current |
3.5 M | 3.24 M | 2.87 M | 2.46 M | 1.75 M | 539 K | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 15.9 M | 12.8 M | 1.31 M | 194 M | 139 M | - | - | - | - |
Total Current Liabilities |
100 M | 86.5 M | 96.8 M | 70 M | 60 M | 22.7 M | 13.8 M | 4.56 M | - | - | - | - | - |
Total Liabilities |
123 M | 112 M | 125 M | 98.8 M | 75.9 M | 35.6 M | 15.1 M | 6.04 M | 142 M | - | - | - | - |
Retained Earnings |
-1.43 B | -1.23 B | -1.05 B | -754 M | -488 M | -296 M | -196 M | -146 M | -120 M | - | - | - | - |
Total Assets |
474 M | 454 M | 429 M | 642 M | 622 M | 316 M | 199 M | 58.9 M | 26.8 M | - | - | - | - |
Cash and Cash Equivalents |
83.5 M | 64.7 M | 87.1 M | 136 M | 120 M | 294 M | 197 M | 57.5 M | 25.8 M | - | - | - | - |
Book Value |
351 M | 342 M | 305 M | 544 M | 546 M | 280 M | 184 M | 52.9 M | -115 M | - | - | - | - |
Total Shareholders Equity |
351 M | 342 M | 305 M | 544 M | 546 M | 280 M | 184 M | -140 M | -115 M | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Deciphera Pharmaceuticals
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
21.4 M | 23.3 M | 24.2 M | 25 M | 25.9 M | 26.7 M | 27.5 M | 27.2 M | 28 M | 27.2 M | 27.9 M | 28.4 M | 28.8 M | 29.4 M | 15.3 M | 15.6 M | 15.9 M | 107 K | 164 K | 244 K | 11.3 M | 17.5 M | 16.9 M | 11.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
105 M | 116 M | 105 M | 109 M | 112 M | 102 M | 102 M | 114 M | 125 M | 103 M | 93.9 M | 92.2 M | 98.8 M | 90.6 M | 66.6 M | 60.7 M | 75.9 M | 44 M | 37.1 M | 29.7 M | 35.6 M | 36.5 M | 37.1 M | 17.6 M | 15.1 M | 15.1 M | 15.1 M | 15.1 M | 6.04 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.47 B | -1.38 B | -1.33 B | -1.28 B | -1.23 B | -1.19 B | -1.14 B | -1.1 B | -1.05 B | -966 M | -886 M | -816 M | -754 M | -692 M | -628 M | -561 M | -488 M | -421 M | -365 M | -343 M | -296 M | -263 M | -239 M | -217 M | -196 M | -196 M | -196 M | -196 M | -146 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
421 M | 498 M | 510 M | 549 M | 454 M | 476 M | 507 M | 385 M | 429 M | 483 M | 541 M | 595 M | 642 M | 660 M | 686 M | 733 M | 622 M | 650 M | 260 M | 270 M | 316 M | 346 M | 368 M | 182 M | 199 M | 199 M | 199 M | 199 M | 58.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
91.2 M | 108 M | 81.4 M | 115 M | 64.7 M | 82.5 M | 110 M | 95.3 M | 87.1 M | 53.2 M | 90.9 M | 202 M | 136 M | 111 M | 155 M | 230 M | 120 M | 174 M | 57.2 M | 82.2 M | 294 M | 321 M | 347 M | 180 M | 197 M | 197 M | 197 M | 197 M | 57.5 M | - | - | - | 25.8 M | - | - | - | 770 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
316 M | 382 M | 404 M | 440 M | 342 M | 374 M | 405 M | 272 M | 305 M | 380 M | 447 M | 503 M | 544 M | 569 M | 620 M | 672 M | 546 M | 606 M | 223 M | 240 M | 280 M | 309 M | 331 M | 165 M | 184 M | 184 M | 184 M | 184 M | 52.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
316 M | 382 M | 404 M | 440 M | 342 M | 374 M | 405 M | 272 M | 305 M | 380 M | 447 M | 503 M | 544 M | 569 M | 620 M | 672 M | 546 M | 606 M | 223 M | 240 M | 280 M | 309 M | 331 M | 165 M | 184 M | 184 M | 184 M | 184 M | -140 M | - | - | - | -115 M | - | - | - | -99.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Deciphera Pharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
